Cell News and Research

RSS

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Osiris Therapeutics, Inc. today announced that it is resuming enrollment in its clinical trial evaluating Prochymal for patients with treatment-resistant Crohn's disease. The findings of an interim analysis showed that for the primary endpoint of disease remission, Prochymal is approaching statistical significance in the intent to treat (ITT) population, and has reached significance in the per protocol population.

6 May 2010

Bone marrow stem cells show promise in multiple sclerosis

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Milk consumption does not cause renal cell cancer

While previous research had suggested that drinking milk was related to factors that may increase the risk of renal cell cancer, results of a recent study exploiting the genetic contribution to variation in milk consumption suggest that this may not be the case.

6 May 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. today reported financial results for its third quarter ended March 31, 2010.

6 May 2010

ImmunoGen proposes underwritten common stock public offering

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it intends to offer, subject to market and other conditions, 8,500,000 shares of its common stock in an underwritten public offering. ImmunoGen expects to grant the underwriters a thirty (30) day option to purchase up to 1,275,000 additional shares to cover over-allotments, if any.

6 May 2010

Novocell is now ViaCyte

Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc.

6 May 2010

Forward's second-quarter gross profit up 50%

Forward Industries, Inc., a designer and distributor of custom carrying case solutions, today announced financial results for its second fiscal quarter ended March 31, 2010.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

New test indicates bone marrow cell therapy may benefit MS patients

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

Scientists use specialized fluorescent protein to study nerve cell activity

Electrical currents are invisible to the naked eye - at least they are when they flow through metal cables. In nerve cells, however, scientists are able to make electrical signals visible. Working with fellow experts from Switzerland and Japan, scientists from the Max Planck Institute for Medical Research in Heidelberg successfully used a specialized fluorescent protein to visualize electrical activity in neurons of living mice.

6 May 2010

Making stem cells in the lab: a training program and a study

Young researchers will now be trained for the first time by the Australian Stem Cell Centre (ASCC) in scientific techniques of using and growing human induced pluripotent stem (iPS) cells in research. This training will be through StemCore iPS Cell Workshop, the ASCC's national facility for the provision of stem cells and advice.

5 May 2010

New breakthrough: Seaweed for treatment of swine flu

In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.

5 May 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).

5 May 2010

BioTime first-quarter total revenue up 159% to $767,127

BioTime, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments.

5 May 2010

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Boehringer Ingelheim and Micromet, Inc. announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

5 May 2010

Cell News and Research

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Bone marrow stem cells show promise in multiple sclerosis

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Milk consumption does not cause renal cell cancer

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

ImmunoGen proposes underwritten common stock public offering

Novocell is now ViaCyte

Forward's second-quarter gross profit up 50%

Update on CEL-SCI's Phase III clinical trial of Multikine

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

New test indicates bone marrow cell therapy may benefit MS patients

Scientists use specialized fluorescent protein to study nerve cell activity

Making stem cells in the lab: a training program and a study

New breakthrough: Seaweed for treatment of swine flu

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

BioTime first-quarter total revenue up 159% to $767,127

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News